Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake. The aim of the study...

Descripción completa

Detalles Bibliográficos
Autores principales: Laroni, Alice, Brogi, Davide, Morra, Vincenzo Brescia, Guidi, Leonello, Pozzilli, Carlo, Comi, Giancarlo, Lugaresi, Alessandra, Turrini, Renato, Raimondi, Debora, Uccelli, Antonio, Mancardi, Giovanni Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005629/
https://www.ncbi.nlm.nih.gov/pubmed/24690227
http://dx.doi.org/10.1186/1471-2377-14-65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005629/
https://www.ncbi.nlm.nih.gov/pubmed/24690227
http://dx.doi.org/10.1186/1471-2377-14-65

Ejemplares similares